Novartis successfully completes acquisition of Endocyte

  • Adds 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer (mCRPC)
  • Strengthens leadership in nuclear medicine and radioligand therapy for treating cancer
  • Complements the robust Advanced Accelerator Applications radioligand therapy pipeline

Basel, December 21, 2018 - Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment.

This site uses cookies and analysis tools to improve the usability of the site. More information. |